Achieve Life Sciences, Inc.
ACHVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAchieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company carries a $537.9M market cap, placing it firmly in the small-cap category. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Market Cap
$537.9M
Beta
2.25
P/E (TTM)
—
P/E (Fwd)
-11.30
EPS (TTM)
$-1.07
EPS (Fwd)
$-0.46
ROE
-496.1%
ROA
-108.4%
Cash
$29.3M
Total Debt
$15.0M
Free CF
-$26.9M
52W Change
34.4%
Annual Financials
Cash vs Debt
With $29.3M in cash and $15.0M in debt, ACHV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$26.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -496.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, ACHV tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ACHV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.